Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal - Pharmaceutical Technology

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system. Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system. At the centrepiece of this deal is Abogen’s autoimmune bispecific T-cell engager, ABO2203. Credit: Taljat David / Shutterstock.com. Unlock FREE Access to Premium Content Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news…

Annabel Kartal Allen · 2026-10-02

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.

Source: Pharmaceutical Technology